Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02664558 · ClinicalTrials.gov registry record · Phase 2
A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
A Phase 2 study, sponsored by Eiger BioPharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02664558: Completed Phase 2 study, sponsored by Eiger BioPharmaceuticals.
NCT02664558 is a Phase 2 study that has completed, run by Eiger BioPharmaceuticals. The registered enrollment target is 61 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02664558, a Phase 2 study, has completed, sponsored by Eiger BioPharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This proof-of-concept study is designed as a Phase 2, multicenter, randomized, double-blind, placebo controlled study comparing ubenimex with placebo in patients with pulmonary arterial hypertension (PAH) (World Health Organization \[WHO\] Group 1) and have a WHO/New York Heart Association (NYHA) Functional Classification (WHO/NYHA-FC) of II or III.
Primary Outcome
Change from Baseline at End of Treatment in PVR Using Worst Case Imputation in the Modified Intent to Treat Population. PVR was assessed by hemodynamic measurements obtained via right heart catheterization.
Interventions
- OTHER placebo
- DRUG ubenimex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-01 |
| Phase | Phase 2 |
What the finished NCT02664558 record still lists
NCT02664558 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02664558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02664558 about?
NCT02664558 is a clinical study titled "A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)". This proof-of-concept study is designed as a Phase 2, multicenter, randomized, double-blind, placebo controlled study comparing ubenimex with placebo in patients with pulmonary arterial hypertension (PAH) (World Health Organization \[WHO\] Group 1) and have a WHO/New York Heart Association (NYHA) Fu...
What is the current status of trial NCT02664558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2016-04. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02664558?
The interventions under investigation include: placebo (OTHER), ubenimex (DRUG).
Who is sponsoring clinical trial NCT02664558?
This trial is sponsored by Eiger BioPharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02664558's enrollment target sits among peer trials
61 1026th of 2000 higher than 974 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia